Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa-Amgen Antibody Deal Worth Up To $520 Million

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko struck a deal worth as much as $520 million with Amgen to outlicense a monoclonal antibody Amgen will develop first for inflammatory disease indications, the firms said March 5
Advertisement

Related Content

Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts
Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts
Takeda Makes $1 Billion Move For Amgen Development Rights
Takeda Makes $1 Billion Move For Amgen Development Rights
Advertisement
UsernamePublicRestriction

Register

SC068118

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel